Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.59 |
| ▸ | PPARA | Q07869 | 3/20 | 0.59 |
| ▸ | EPOR | P19235 | 6/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | PPARD | Q03181 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | LAP3 | P28838 | 1/20 | 0.52 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2438787 | 0.89 | LTA4H (0.60) | PPARGPPARAEPORALOX5PTGS1 | |
| SCHEMBL19930028 | 0.88 | MAOB (0.63) | PPARGPPARAALOX5FFAR1FFAR4 | |
| SCHEMBL13110183 | 0.87 | EPOR (0.72) | PPARGPPARAEPORALOX5PTGS1 | |
| SCHEMBL2319694 | 0.85 | CYP1A2 (0.53) | PTGS1 | |
| SCHEMBL8202673 | 0.85 | CYP1A2 (0.53) | PTGS1 | |
| SCHEMBL31062607 | 0.84 | LDHA (0.58) | PPARGPPARA | |
| SCHEMBL6483824 | 0.84 | MAOB (0.62) | PPARGPPARAALOX5PTGS1PTGS2 | |
| SCHEMBL19930052 | 0.84 | MAOB (0.59) | PPARGPPARAFFAR1FFAR4MAOB | |
| SCHEMBL2437662 | 0.84 | MAOB (0.54) | PPARGPPARAEPORALOX5PTGS1 | |
| SCHEMBL27799946 | 0.84 | SLC7A5 (0.49) | PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140194349-A1 | HIV Protease Inhibiting Compounds | ABBVIE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| EP-2266971-A2 | Hiv protease inhibiting compounds | Abbott Laboratories (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-1287006-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2007-10-24 | — | — | EP | disclosed |
| US-7138547-B2 | Antitumoral compounds | PHARMA MAR, S.A. | 2006-11-21 | — | — | US | disclosed |
| US-20040048834-A1 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048834-A1 | Antitumoral compounds | HCCS, MSR1, SUCNR1 | PPARG 3424/4885PPARA 3797/4885EPOR 62/4885 |
| US-20140194349-A1 | HIV Protease Inhibiting Compounds | SERPINB1, HPN, DNPEP | PPARG 4686/4885PPARA 4628/4885EPOR 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.